<DOC>
	<DOCNO>NCT00893399</DOCNO>
	<brief_summary>Randomized Phase-III , two-arm , open-label , multi-center study adult patient AML NPM1 mutation . Before Amendment No . 4 ( December 2013 ) : Primary Efficacy Objective : - Evaluation efficacy base event-free survival ( EFS ) induction consolidation chemotherapy plus all-trans retinoic acid ( ATRA ) without gemtuzumab ozogamicin ( GO ) adult patient acute myeloid leukemia ( AML ) mutant nucleophosmin-1 ( NPM1 ) After Amendment No . 4 ( December 2013 ) : Primary Efficacy Objective : - Evaluation efficacy base overall survival ( OS ) induction consolidation chemotherapy plus all-trans retinoic acid ( ATRA ) without gemtuzumab ozogamicin ( GO ) adult patient acute myeloid leukemia ( AML ) mutant nucleophosmin-1 ( NPM1 )</brief_summary>
	<brief_title>Study Chemotherapy Combination With All-trans Retinoic Acid ( ATRA ) With Without Gemtuzumab Ozogamicin Patients With Acute Myeloid Leukemia ( AML ) Mutant Nucleophosmin-1 ( NPM1 ) Gene Mutation</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<criteria>Patients confirm diagnosis acute myeloid leukemia accord World Health Organization ( WHO ) classification . Presence NPM1 mutation assess one central AMLSG reference laboratory . Age â‰¥ 18 year . There upper age limit . No prior chemotherapy leukemia except hydroxyurea control hyperleukocytosis need 5 day diagnostic screening phase . Nonpregnant nonnursing . Women childbearing potential ( WOCBP ) must negative serum urine pregnancy test within sensitivity least 25 mIU/mL within 72 hour prior registration . Female patient reproductive age male patient must agree avoid get pregnant father child therapy within one year last dose chemotherapy . Women childbearing potential must either commit continued abstinence heterosexual intercourse begin two acceptable method birth control : one highly effective method ( e.g. , IUD , hormonal , tubal ligation , partner 's vasectomy ) , one additional effective method ( e.g. , latex condom , diaphragm , cervical cap ) . `` Women childbearing potential '' define sexually active mature woman undergone hysterectomy menses time precede 24 consecutive month . Men must use latex condom sexual contact woman childbearing potential , even undergone successful vasectomy . Signed write informed consent . AML recurrent genetic change ( accord WHO 2008 ) : AML ( 8 ; 21 ) ( q22 ; q22 ) ; RUNX1RUNX1T1 AML inv ( 16 ) ( p13.1q22 ) ( 16 ; 16 ) ( p13.1 ; q22 ) ; CBFBMYH11 AML ( 15 ; 17 ) ( q22 ; q12 ) ; PMLRARA ( translocation involve RARA ) AML ( 9 ; 11 ) ( p22 ; q23 ) ; MLLT3MLL ( translocation involve MLL ) AML ( 6 ; 9 ) ( p23 ; q34 ) ; DEKNUP214 AML inv ( 3 ) ( q21q26.2 ) ( 3 ; 3 ) ( q21 ; q26.2 ) ; RPN1EVI1 . Performance status WHO &gt; 2 . Patients ejection fraction &lt; 50 % MUGA ECHO scan within 14 day day 1 . Organ insufficiency : creatinine &gt; 1.5x upper normal serum level bilirubin , AST ALP &gt; 2.5x upper normal serum level , attributable AML heart failure NYHA III/IV severe obstructive restrictive ventilation disorder . Uncontrolled infection . Severe neurological psychiatric disorder interfere ability give informed consent . Patients `` currently active '' second malignancy nonmelanoma skin cancer . Patients consider `` currently active '' malignancy complete therapy consider physician less 30 % risk relapse within one year . Known positive HIV , active HBV , HCV , Hepatitis A infection . Bleeding disorder independent leukemia . No consent registration , storage process individual diseasecharacteristics course well information family physician study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>adult patient</keyword>
	<keyword>NPM1 mutation</keyword>
</DOC>